SUSPECT ADVERSE REACTION REPORT

PA-Tolmar-TLM-2025-04091

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET		
		Day	Month	Year			Day	Month	Year
L-J	PANAMA	29	Sep	1949	75	Male	24	Jun	2025

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Bone metastases (Bone metastases (10005993), Metastases to bone (10027452))
(25/Jul/2025 -) - Not Recovered/Not Resolved/Ongoing
2) Increased Prostatic Antigen values (Prostatic specific antigen increased (10036975), Prostatic specific antigen increased (10036975))
(24/Jun/2025 -) - Not Recovered/Not Resolved/Ongoing

Cont..

8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION

- ☐ PATIENT DIED
- ☑ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☑ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (45 Milligram, Injection)(Unknown)

Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)

1) (45 milligram(s), 1 in 6 Month)

16. ROUTE(S) OF ADMINISTRATION

1) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Prostate cancer [10060862 - Prostate cancer]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
1) (26/Jan/2024 - Ongoing)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

No concomitants used/reported

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
Anjan.Chatterjee@tolmar.comand+1--9702124900

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED	24b. MFR CONTROL NO.
☐ YES ☐ NO	PA-Tolmar-TLM-2025-04091
24c. DATE RECEIVED BY MANUFACTURER: 30/Jul/2025	24d. REPORT SOURCE: ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL
DATE OF THIS REPORT: 02/Aug/2025	25a. REPORT TYPE: ☐ INITIAL ☑ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This study report from Panama was received by Adium (Reference number: PA-ADIUM-PA-0068-20250624) via Patient Support Program on 24-Jun-2025 from a consumer (patient or family member) (non-healthcare professional) regarding an elderly 75-year-old male patient who experienced non-serious event of "Increased Prostatic Antigen values" (prostatic specific antigen increased) during Eligard (leuprolide acetate) 45 mg therapy for prostate cancer. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 25-Jun-2025.

The patient's medical history was unknown and current condition included prostate cancer.

Concomitant medication was unknown.

On 26-Jan-2024, the patient began receiving Eligard 45 mg, every 6 months via subcutaneous route for prostate cancer (Lot number and Expiration dates were not provided).

On 24-Jun-2025, the patient's prostate-specific antigen values increased severely with a result of 76.

Corrective treatment included to start bicalutamide as doctor instructed.

Relevant test results included:
On 24-Jun-2025: PSA: increased prostatic antigen with a result of 76 (Ref range: not provided).

Action taken with Eligard in response to event was dose not changed. De-challenge and re-challenge were not applicable.

The outcome of prostatic specific antigen increased was not recovered.

The reporter did not assess the seriousness of prostatic specific antigen increased.

The reporter assessed the causality of prostatic specific antigen increased in relationship to Eligard and Eligard unspecified device as related.

No further information is expected as the reporter did not consent to be contacted for follow-up.

Listedness:
Prostatic specific antigen increased>Eligard>listed as per CCDS>07-Nov-2024
Prostatic specific antigen increased>Eligard>listed as per USPI>Feb-2025
Prostatic specific antigen increased>Eligard unspecified device>listed as per USPI>Feb-2025
Prostatic specific antigen increased>Eligard>listed as per Canadian monograph>02-Apr-2

On 30-Jul-2025, follow-up information was received by Adium via Patient Support Program "ASOFARMA A TU LADO" (Reference number: PA-ADIUM-PA-0068-20250624) from a Consumer (non-healthcare professional) and sent to Tolmar on 31-Jul-2025. New information included: Added new serious (life-threatening and other medically important condition) event "Bone metastases" (Metastases to bone) and narrative was updated.

On 25-Jul-2025, the patient had bone metastases.

On 30-Jul-2025, the patient reported that he was referred to the cancer institute because the examination indicated that he had bone metastases. Treatment was very expensive and they could not afford it. No further details were available.

Corrective treatment was not reported.

Relevant test results included:
On an unknown date, examination: indicated bone metastases (Ref. range: Not provided).

Action taken with Eligard in response to the event metastases to bone was dose not changed. De-challenge and re-challenge were not applicable.

The outcome of the event metastases to bone was not resolved.

The reporter assessed the seriousness of the event metastases to bone as life threatening.

The reporter provided the causality of the event metastases to bone as related in relationship to Eligard and Eligard Unspecified device.

No further information is expected as consent to be contacted was not provided.

Listedness: Prostatic specific antigen increased listedness is retained

Metastases to bone>Eligard>listed as per CCDS>07-Nov-2024
Metastases to bone>Eligard>listed as per USPI>Feb-2025

Continuation Sheet for CIOMS report

Metastases to bone>Eligard unspecified device>listed as per USPI>Feb-2025
Metastases to bone>Eligard>listed as per Canadian monograph>02-Apr-2

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): This is regarding an elderly 75-year-old female patient who had prostate specific antigen increased (Increased Prostatic Antigen values), during Eligard (leuprolide acetate) 45 mg therapy for prostate cancer. Tolmar assessed the event as non-serious since it does not meet the ICH seriousness criteria and is not an IME event. The reported event was assessed as not related to Eligard (drug and device) as the event can be explained by underlying prostate cancer.

Follow up received. Patient was referred to the cancer institute because the examination indicated he had bone metastases, treatment is very expensive, and he cannot afford it. No significant information to affect previously assessed causality, hence causality is retained.

Additional Information (Continuation...)

Lab Result :

Test Name	Test Date	Test Result	Normal Value
EXAMINATION			
PSA	24/Jun/2025		

Test Result (Code) / Result Unstructured Data (free text) :

1) Test Name: EXAMINATION

Result Unstructured Data (free text) : Indicated bone metastases

Test Date:

2) Test Name: PSA

Result Unstructured Data (free text) : Increased Prostatic Antigen with a result of 76

Test Date: 24/Jun/2025

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug : Eligard® (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form Strength : 1) 45 Milligram
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Daily Dose : (45 milligram(s), 1 in 6 Month)
Route of Admin : 1) Subcutaneous
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Therapy Dates : 1) From : 26/Jan/2024 To :Continuing
Action(s) Taken With Drug : Dose not changed

Causality

1) Bone metastases (Bone metastases - 10005993, Metastases to bone - 10027452)
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) Increased Prostatic Antigen values (Prostatic specific antigen increased - 10036975, Prostatic specific antigen increased - 10036975)
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Bone metastases
CORE UnLabeled
2) Increased Prostatic Antigen values
CORE Labeled

Continuation Sheet for CIOMS report

2) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Action(s) Taken With Drug : Not applicable

Causality

1) Bone metastases (Bone metastases - 10005993, Metastases to bone - 10027452)
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) Increased Prostatic Antigen values (Prostatic specific antigen increased - 10036975, Prostatic specific antigen increased - 10036975)
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Bone metastases
CORE
2) Increased Prostatic Antigen values
CORE

15. DAILY DOSE(S) (Continuation...)

Dosage Text :

Drug 1 :Eligard®

1) 45 Milligrams every 6 Months